Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug that enhances glutamate transmission in brain being evaluated for fragile X

28.08.2002


Rush is one of only two sites in nation testing the drug that may provide new treatment option

Physicians at Rush-Presbyterian St. Luke’s Medical Center have begun to recruit patients as part of a clinical research study that will evaluate the effectiveness of a new drug as a potential treatment for fragile X syndrome and autism.

The trials are taking place at Rush and the University of California, Davis. The principal investigators in the study are Dr. Elizabeth Berry-Kravis, a pediatric neurologist at Rush-Presbyterian St. Luke’s Medical Center; and Dr. Randi J. Hagerman, medical director, M.I.N.D. Institute, School of Medicine, University of California, Davis. Dr. Edwin Cook an expert in autism at the University of Chicago contributed to the development of the clinical protocol.



"Currently there are no therapies on the market to treat cognitive deficits associated with fragile X syndrome or autism," said Berry-Kravis. "However, in the past five years, basic research has led to an improved understanding of these diseases and a number of scientists have suggested that the use of a drug to enhance glutamate transmission could be beneficial." The study will evaluate CX516 (Ampalex®), an Ampakine® compound, which has been proven to enhance glutamate transmission in the brain through activation of AMPA receptors. Ampalex® is made by Cortex Pharmaceuticals which will provide the study medication. The research is funded by the FRAXA Research Foundation.

Fragile X is an inherited disorder and is the most common cause of inherited mental retardation, affecting 1 in 2,000 males and 1 and 4,000 females. Symptoms of fragile X syndrome include mental impairment ranging from learning disabilities to mental retardation, attention deficit and hyperactivity, anxiety and unstable mood, autistic-like behaviors, long face, large ears, flat feet, and hyperextensible joints, especially fingers. "Once you have a patient with fragile X syndrome, that’s a big red flag because that means the mutation has been in the family in a silent form for years," says Berry-Kravis.

Males are typically more severely affected than females. Although most males have mental retardation, only one-half of females have intellectual impairment (which tends to be milder in females); the rest have either normal IQ or learning disabilities. Emotional and behavioral problems are common in both sexes. Currently there are no therapeutic treatments for the learning problems associated with the disease, although medications for anxiety and ADHD are used to treat behavioral symptoms. Rush-Presbyterian-St. Luke’s Medical Center is the only clinical site for care of fragile X patients in the Chicago area.

Autism is a complex developmental disability that typically appears during the first three years of life. The result of a neurological disorder that affects the functioning of the brain, autism and its associated behaviors have been estimated to occur in as many as 2 to 6 in 1,000 individuals. Autism is four times more prevalent in males than in females.

A variety of scientific evidence suggests that increasing glutamate neuronal transmission may be beneficial in autism and in fragile X syndrome. Imaging studies demonstrate that areas of the brain that are extremely rich in glutamate transmission are less active in autistic patients. Molecular studies suggest that although genes involved in the AMPA-type glutamate receptor are more active in autistic patients, the density of AMPA-type glutamate receptors is decreased. Drugs that reduce glutamatergic transmission induce symptoms similar to those seen in autistic patients. Taken together, these facts suggest that enhancing AMPA receptor activity may be beneficial in autistic patients.

The scientific logic for using an AMPA receptor activator in fragile X syndrome is even more compelling because of recent findings regarding the direct impact of the genetic defect in fragile X on neural cell activity. The genetic defect results in the reduction or absence of an important protein, FMRP. FMRP is believed to play an important role in allowing normal levels of AMPA receptor proteins to be made - in the absence of FMRP, AMPA receptors are decreased and show lower activity levels. The abnormal AMPA receptor activity is likely related to the abnormal connections seen between neurons in the brains of those with fragile X syndrome. Increasing the activity of AMPA receptors with an Ampakine® may to some degree overcome the reduced number of AMPA receptors, with resulting improvements in brain connections in individuals with fragile X syndrome.

The design of the Phase II clinical study is a randomized double-blind placebo controlled trial lasting four weeks. Fifty patients from the Chicago area will be recruited for the study. It is anticipated that enrollment will occur over a two-year period. Outcome measures will include testing in four domains of attention and executive function; spatial and verbal/auditory memory; language; and behavior.

John Pontarelli | EurekAlert!

More articles from Health and Medicine:

nachricht Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Tracking movement of immune cells identifies key first steps in inflammatory arthritis

23.01.2017 | Health and Medicine

Electrocatalysis can advance green transition

23.01.2017 | Physics and Astronomy

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>